Phase 1/2 study of high-dose palifermin for GVHD prophylaxis in patients undergoing HLA-matched unrelated donor HCT.
Schulz E, Curtis LM, Holtzman NG, Steinberg SM, Wloka K, Ostojic A, Mina A, El Jurdi N, Pirsl F, Carpenter A, Golagha M, Sirajuddin A, Heller T, Shaffer BC, Hakim FT, Rubin JS, Gress RE, Pavletic SZ.
Schulz E, et al. Among authors: rubin js.
Blood. 2025 Aug 21;146(8):944-950. doi: 10.1182/blood.2024028303.
Blood. 2025.
PMID: 40331908
Clinical Trial.